TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

Completed · Phase 1/Phase 2

Conditions studied: Ovarian Neoplasms

In brief

This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.

Key facts

Study ID

NCT00052065

Run by

Telik

People needed

28

Starts

2003-02-01

Expected to finish

2006-03-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube cancer or primary peritoneal cancer
• Recurrent epithelial ovarian cancer or persistent disease following primary treatment
• At least one, but no more than four, prior platinum-containing chemotherapy regimens
• At least one prior taxane-containing regimen

You may not qualify if…

• A history of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which the patient has been disease-free for 2 years
• Known leptomeningeal metastases or carcinomatous meningitis
• Have received prior Doxil or other liposomal doxorubicin
• Having received whole pelvis radiation therapy

Where it is running

• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.